Health · Pharma & Biotech · 7 hrs ago
Expert warns of future fight over access to newer obesity drugs
Ken Shadlen warns that access to obesity medicines could become a global battleground.
Shadlen is a London School of Economics professor who studies pharmaceutical and health regulation.
Lower-cost generic versions of semaglutide are now available in some countries and are expected to reach others soon.
Semaglutide is sold by Novo Nordisk as Wegovy to help treat obesity.
Drugmakers are developing newer GLP-1 medicines that are forecast to work better, cause fewer side effects or be easier to use.
These changes could help more people get support for losing weight, but access may be especially contested in lower-income countries.
Drugmakers, governments and patients may soon face challenges over who can get these medicines.
Ken Shadlen, a London School of Economics professor, warns that obesity medicines could become a major battleground over access in lower-income countries.
Lower-cost generic versions of semaglutide, sold as Wegovy for obesity, have started becoming available in some countries.
Those generic versions are expected to arrive in other countries soon.
Drug companies are developing newer GLP-1 medicines that are forecast to be more effective, cause fewer side effects, or be easier to use.
- Who
- Ken Shadlen, a London School of Economics professor who studies pharmaceutical and health regulation.
- What
- He warns that access to obesity medicines could become a major issue in lower-income countries.
- When
- Generic semaglutide versions started becoming available in some countries over the past few months.
- Where
- Some countries; others are expected to receive generic versions soon. The warning concerns access in lower-income countries.
- Why
- Newer obesity medicines may raise challenges for drugmakers, governments, and patients over access.
This story does not have two clearly opposing sides.
Lower-cost generic versions of semaglutide started becoming available in some countries.
Generic versions of semaglutide are expected to arrive in other countries.
- Expert
- Ken Shadlen, London School of Economics professor
- Drug
- Semaglutide, sold as Wegovy by Novo Nordisk for combating obesity
- Access concern
- Lower-income countries
- New medicines
- GLP-1 drugs are forecast to be more effective, cause fewer side effects, or be easier to administer